ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Interferon beta-1a

Also written as “Rebif®”, “RNF” and “Rebif”.

Its studies are mostly in Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting · COVID-19 · Colitis, Ulcerative · Pneumonia, Viral, led by 7 companies.

Drug pageInterferon beta-1a: every studyMany companies study it; this page follows only the 53 they lead. All 82 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 13, 200553 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogenits history only230 open or runningphase 4since Sep 13, 2005Dec 15, 2004none ahead
Merck KGaA, Darmstadt, Germany210 open or runningphase 4since Feb 23, 2004Feb 23, 2004none ahead
Faron Pharmaceuticalsits history only30 open or runningphase 3since Nov 24, 2015Nov 24, 2015none ahead
Biocadits history only20 open or runningphase 3since May 29, 2015Jan 10, 2013none ahead
Cinnagenits history only20 open or runningphase 3since Jan 17, 2022Jul 14, 2018none ahead
Azidus Brasilits history only10 open or runningphase 1since Nov 13, 2009Nov 13, 2009none ahead
Trio Medicinesits history only10 open or runningphase 1since May 20, 2013May 20, 2013none ahead

Also a collaborator on its studies: Toray Industries, Pfizer, Gesellschaft für Therapieforschung mbH, Merck Serono S.P.A., Italy, Merck Serono S.A.S, France, EMD Serono Canada, Elan Pharmaceuticals, Merck Pte. Ltd., Singapore and Merck Serono International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck KGaA, Darmstadt, Germany only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Feb 23, 2004.

  1. Aug 21, 2006Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNCT00367484 · 460 enrolled
  2. Nov 27, 2006Phase 3 study in Multiple SclerosisNCT00404352 · 517 enrolled · Argentina, Australia, Austria and more
  3. Feb 26, 2007Phase 3 study in Multiple Sclerosis, Relapsing-RemittingNCT00441103 · 180 enrolled
  4. Jul 30, 2008Phase 3 study in Multiple SclerosisNCT00725985 · 617 enrolled · United States, Argentina, Austria and more
  5. Dec 22, 2008Phase 3 study in Multiple SclerosisNCT00813709 · 402 enrolled · Argentina, Austria, Belgium and more
  6. Feb 24, 2010Phase 2 study in Alzheimer DiseaseNCT01075763 · 42 enrolled · Italy
  7. Mar 10, 2010Phase 4 study in Multiple SclerosisNCT01085318 · 38 enrolled · United States
  8. Jun 10, 2010Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNCT01142466 · 30 enrolled
  9. Sep 13, 2010Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNCT01201343 · 79 enrolled
  10. Jan 26, 2011Phase 2 study in Multiple Sclerosis, Relapsing-RemittingNCT01285401 · 260 enrolled · Austria, Denmark, Estonia and more
  11. Feb 12, 2013Phase 4 study in Multiple SclerosisNCT01791244 · 93 enrolled · Germany, Sweden
  12. Feb 13, 2014Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNCT02064816 · 200 enrolled · Germany
  13. Apr 15, 2014Phase 4 study in Multiple SclerosisNCT02117050 · 1 enrolled · United States
  14. Sep 29, 2014Phase 4 study in Relapsing Multiple SclerosisNCT02254304 · 106 enrolled · Germany

TargetBeta

“A recombinant form of the endogenous cytokine human interferon (IFN) beta-1a, with antiproliferative, antiviral and immunomodulating activities”NCIt, by rule
“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule

Studies

All 21 Merck KGaA, Darmstadt, Germany leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02254304Relapsing Multiple Sclerosis · Germany4CompletedAug 20, 2016106
NCT02117050Multiple Sclerosis · United States4TerminatedApr 20151
NCT02064816Multiple Sclerosis, Relapsing-Remitting · Germany4CompletedApr 30, 2016200
NCT01791244Multiple Sclerosis · Germany, Sweden4CompletedFeb 29, 201693
NCT01285401Multiple Sclerosis, Relapsing-Remitting · Austria, Denmark, Estonia and more2CompletedApr 2015260
NCT01201343Multiple Sclerosis, Relapsing-Remitting4CompletedJul 201079
NCT01142466Multiple Sclerosis, Relapsing-Remitting4CompletedDec 200930
NCT01085318Multiple Sclerosis · United States4CompletedFeb 29, 201238
NCT01075763Alzheimer Disease · Italy2CompletedMay 200842
NCT00813709Multiple Sclerosis · Argentina, Austria, Belgium and more3CompletedAug 2011402
NCT00725985Multiple Sclerosis · United States, Argentina, Austria and more3CompletedJul 31, 2011617
NCT00441103Multiple Sclerosis, Relapsing-Remitting3CompletedNov 2008180
NCT00404352Multiple Sclerosis · Argentina, Australia, Austria and more3CompletedAug 2010517
NCT00367484Multiple Sclerosis, Relapsing-Remitting4CompletedJan 2006460
NCT00304252Crohn Disease · Germany, Italy, Sweden and more2Terminated192
NCT00303381Colitis, Ulcerative · Germany, Israel, Netherlands and more2CompletedJan 2003194
NCT00292266Multiple Sclerosis, Relapsing-Remitting3CompletedJun 2002677
NCT00287079Clinically Isolated Syndrome · Canada3CompletedNov 200835
NCT00249860Hepatitis C3CompletedAug 2005257
NCT00101959Multiple Sclerosis, Relapsing-Remitting4Withdrawn0
NCT00078338Multiple Sclerosis, Relapsing-Remitting · United States, Argentina, Austria and more4CompletedNov 28, 2006764

How it is read

Names in the registry

  • “Interferon beta-1a”, 11 entries
  • “Rebif®”, 7 entries
  • “RNF”, 5 entries
  • “Rebif”, 4 entries
  • “SNG001”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.